Stocks-ALVR-Allovir Inc

ALVR Allovir Inc

6.50 -0.15 (-2.26%)
Delayed Prices By NASDAQ, in USD Market Closed
Invest
11.88% Past Week
Created with Highcharts 4.2.7 /Highstock 4.2.7
Market Cap
602.44M
Day’s Range
6.28
-
6.68
52W Range
3.15
-
10.22
Volume (3M)
239.41K
Price-Earnings Ratio
-
Revenue
-

Allovir Inc Latest News

View All
Pinned Post
eToro Team
🎉 Here’s a little preview introducing 16 YEARS of INVESTING on eToro 😏🤑 With love, - The eToro Team youtu.be/UFYvpJxh2qA
Like CommentShare
Show more comments2 of 65
1 reply
1 reply
null
.
Top Discussions
MarketUpdates
Edited
$ALVR (Allovir Inc) Q4 2022 earnings report is expected to be released
9
FEB
REPORTS
Allovir Inc Q4 2022 earnings report is expected to be released before market open
Notify me
ALVR
ALVR
Allovir Inc
6.50
-0.15
(-2.26%)
Trade
ALVR
Allovir Inc
6.49
-0.15 (-2.26%)
Trade
MarketUpdates
Edited
$ALVR (Allovir Inc) Q4 2022 earnings report is expected to be released
ALVR
Allovir Inc
6.49
-0.15 (-2.26%)
Trade
Iurii Drabik
Edited
The top 10 stocks losers this week on eToro: 1. $ORP.PA (Orpea) (-44.53%) 2. $LRN (Stride Inc.) (-29.96%) 3. $BW (Babcock & Wilcox Enterprises Inc) (-27.67%) 4. $META (Meta Platforms Inc) (-25.54%) 5. $ALVR (Allovir Inc) (-24.68%) 6. $SIVB (SVB Financial Group) (-24.16%) 7. $GOTU (Gaotu Techedu Inc.)... Show More
Like CommentShare
null
.
MarketUpdates
Edited
$ALVR (Allovir Inc) Q3 2022 earnings report is expected to be released
4
NOV
REPORTS
Allovir Inc Q3 2022 earnings report released before market open
ALVR
ALVR
Allovir Inc
6.50
-0.15
(-2.26%)
Trade
ALVR
Allovir Inc
6.49
-0.15 (-2.26%)
Trade
MarketUpdates
Edited
$ALVR (Allovir Inc) Q3 2022 earnings report is expected to be released
ALVR
Allovir Inc
6.49
-0.15 (-2.26%)
Trade

About Allovir Inc

AlloVir is an American healthcare company and is one of the leading names around the globe in the development of Virus-Specific T-cell (VST) immunotherapies. Founded in 2013 and headquartered in Cambridge, Massachusetts, the firm is focussed on developing highly innovative, allogeneic, off-the-shelf VST therapy candidates which target twelve devastating viral infections with both treatment and prevention. The firm’s work is aimed at helping patients with T-cell deficiencies, many of whom currently have limited treatment options or no viable treatment at all. The company launched publicly in 2020 with an upsized IPO that raised $276.25m. Allovir is listed on the NASDAQ GS and trades its stock under the ticker ALVR. In November 2020 the ALVR share price was $34.55 and the company had a market cap of $2.13bn. The company’s platform is highly efficient, practising advanced VST profiling and antigen selection to induce the strongest T-cell immune responses. Their CytokinTM donor selection process ensures an efficient selection of carefully-screened donors. The firm maintains a pipeline of therapeutic candidates in pre-clinical and clinical trials targeting high-risk individuals, such as organ transplant patients and those suffering various chronic illnesses. Add ALVR stock to your eToro watchlist to get news and updates on this instrument.
107
Employees
Waltham, Massachusetts, US
HQ
2013
Founded
Diana M. Brainard, MD
CEO
Show More

Upcoming Earnings

9
FEB
REPORTS
Allovir Inc Q4 2022 earnings report is expected to be released before market open

ESG: A New Source of Insight

Get insight into a company's sustainability using ESG (environmental, social, and governance) scores.
0
100
43
Low
Industry 
Avg. 45 
34
Environment
33
Social
57
Governance

People Also Bought